[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biohaven Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":4,"overallStatus":22,"whyStopped":4,"lastUpdateSubmitDate":23,"lastUpdatePostDateStruct":24,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":27,"locationsCount":4},"100518772",false,"NCT06034886","Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Intermediate-Size Patient Population Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Key Inclusion Criteria:\n\n* Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.\n* Adequate hepatic function.\n\nKey Exclusion Criteria:\n\n* Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.\n* Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).",[20,21],"SCA","Spinocerebellar Ataxias","AVAILABLE","2026-01-08",{"date":25,"type":26},"2026-01-09","ACTUAL",{"name":28,"class":29},"Biohaven Pharmaceuticals, Inc.","INDUSTRY",""]